University of California San Francisco
Give to UCSF
A previously unidentifiable type of low-grade inflammation may explain why common anti-inflammatory drugs such as aspirin have shown promise against some types of cancer – even when patients don’t display typical signs of inflammation.
UC San Francisco researchers have shed light on how the immune system of a fetus can run amok, triggering inflammation in the developing intestines that protrude outside of the body through a hole beside the belly button.
With one drug to shut down its progression and another to undo its damage, plus a worldwide effort stalking the origins of multiple sclerosis, MS doesn’t stand a chance.
Renowned UCSF immunologist Jeffrey Bluestone, PhD, has been named president and CEO of the Parker Institute for Cancer Immunotherapy, a national initiative launched with a $250 million grant from The Parker Foundation, established by Silicon Valley entrepreneur Sean Parker.
Scientists at UC San Francisco have been able to directly observe, for the first time, how invasive cancer cells create a beachhead as they migrate to the lung in a mouse model of metastatic cancer.
Research by UCSF scientists has opened up a surprising new avenue for potential therapies to reduce the risk of type 2 diabetes and other metabolic disorders that are associated with chronic tissue inflammation in obesity.
Leading microbiome researchers recently came to UCSF to share the newest insights about how improving our relationship with our bodies’ microbial ecosystems could be the next big breakthrough in treating metabolic disease.
UCSF scientists have created a new class of highly customizable biological sensors that can be used to form “logic gates” inside cells of the immune system, giving these cells the capability to home in on and kill a wide range of cancer cells while preventing them from attacking normal tissue.
The cells that create myelin, a fatty material that insulates nerve fibers in the brain’s white matter, migrate into the developing brain by climbing and swinging on blood vessels, according to new research led by UCSF scientists.
In a bid to end the worst epidemic in modern times, the Foundation for AIDS Research (amfAR) is funding an ambitious effort based in San Francisco to eliminate the human immunodeficiency virus (HIV) from those who are infected.
In the first U.S. safety trial of a new form of immunotherapy for type 1 diabetes, patients experienced no serious adverse reactions after receiving infusions of as many as 2.6 billion cells that had been specially selected to protect the body’s ability to produce insulin.
A wave of specialized immune cells entering the skin in early life may induce tolerance to the hundreds of species of so-called friendly bacteria that live on the surface of the body.
A $10 million gift from The Parker Foundation, founded by Silicon Valley entrepreneur and philanthropist Sean Parker, will establish a new research laboratory within the UCSF Diabetes Center devoted to understanding autoimmunity.
To help stop the spread of antibiotic resistance, UCSF scientists are urging hospitals around the country to stop buying meat from animals that were given antibiotics for growth promotion.
A virus is nature’s efficient little killer. They’re really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
UCSF researchers have engineered a molecular “on switch” that allows tight control over the actions of T cells, immune system cells that have shown great potential as therapies for cancer.
A rare, deadly form of skin cancer known as desmoplasmic melanoma may possess the highest burden of gene mutations of any cancer, suggesting that immunotherapy may be a promising approach for treatment, according to an international team led by UCSF scientists.
A new study led by a UCSF sleep researcher supports what parents have been saying for centuries: to avoid getting sick, be sure to get enough sleep.
UCSF researchers have discovered that the adaptive immune system plays an active role in guiding the normal development of mammary glands, the only organs that develop predominantly after birth, beginning at puberty.
Two demonstration projects that aim to yield quick results for patients have been selected by the new California Initiative to Advance Precision Medicine, a public-private effort launched by Governor Edmund G. Brown Jr.
In a project spearheaded by investigators at UCSF, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
A blood-borne molecule that increases in abundance as we age blocks regeneration of brain cells and promotes cognitive decline, suggests a new study.
UC San Francisco scientists have identified characteristics of a family of daughter cells, called MPPs, which are the first to arise from stem cells within bone marrow that generate the entire blood system.
A team led by researchers from UCSF, Organic Health Response and Microclinic International is reporting results of a study that showed significant benefits of microclinics – an innovative intervention that mobilized rural Kenyan HIV patients’ informal social networks to support their staying in care.
A team led by UCSF researchers has discovered how a commonly administered vaccine protects against acute lymphoblastic leukemia, the most common type of childhood cancer.
A research team led by scientists from UCSF, Baylor College of Medicine, and Texas Children’s Hospital has identified a new autoimmune syndrome characterized by a combination of severe lung disease and arthritis that currently has no therapy.
Immune cells perform a previously unsuspected role in the brain that may contribute to obesity, according to a new study by UCSF researchers.
Scores of autoimmune diseases mysteriously cause the immune system to harm tissues within our own bodies. Now, a new study pinpoints the complex genetic origins for many of these diseases.
A newly discovered population of immune cells in tumors is associated with less severe cancer outcomes in humans, and may have therapeutic potential, according to a new UCSF study.
A scientific team led by UCSF researchers found that regulatory T cells, a specialized subset of immune cells, suppress inflammation and muscle injury in a mouse model of Duchenne muscular dystrophy.